title: Corticotrophin releasing hormone (CRH1-41) stimulates the secretion of adrenocorticotrophin, vasopressin and oxytocin but not adrenocorticotrophin precursors: evidence from petrosal sinus sampling in man.
abstract: To examine the relationship between corticotrophin releasing hormone (CRH), arginine vasopressin (AVP) and oxytocin (OXT) we have studied the responses of adenohypophyseal and neurohypophyseal hormones to CRH in eight patients (age 26-64 years, six female) with suspected pituitary-dependent Cushing's syndrome during bilateral, simultaneous inferior petrosal sinus catheterization. Blood samples were taken from both petrosal sinuses and a peripheral vein before, and at 5-min intervals for 15 min after, an intravenous injection of 100 micrograms human CRH1-41. CRH increased sinus AVP concentrations in all eight patients and OXT concentrations in four of five patients studied. Although AVP concentrations often increased in both sinuses, the side of maximal AVP rise was termed side(max-AVP). CRH did not affect peripheral or petrosal sinus mean concentrations of LH, FSH, GH or TSH. While there was no change in mean peripheral concentrations of AVP, OXT, ACTH, ACTH precursors or prolactin after CRH, sinus concentrations of OXT, ACTH and prolactin on side(max-AVP) were markedly elevated over contralateral values. CRH did not increase mean sinus concentrations of ACTH precursors. In seven patients with either no radiological abnormality or the pituitary fossa or a small adenoma the mean ACTH precursor/ACTH ratio in blood sampled from all sites was 2.1 +/- 0.16 (mean +/- SEM, n = 50). In a patient with a large, locally invasive tumour the mean ACTH precursor/ACTH molar ratio was 32.1 +/- 1.3 (n = 12; P less than 0.001), suggesting that alterations in this molar ratio may reflect the biological properties of the tumour. The source of CRH-stimulatable AVP and OXT remains uncertain.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Medicine, St George's Hospital Medical School, London, UK.
authors.forename: S S
authors.initials: SS
authors.lastname: Nussey
authors.forename: S R
authors.initials: SR
authors.lastname: Page
authors.forename: D B
authors.initials: DB
authors.lastname: Peterson
authors.forename: J
authors.initials: J
authors.lastname: Byrne
authors.forename: S R
authors.initials: SR
authors.lastname: Crosby
authors.forename: A
authors.initials: A
authors.lastname: White
authors.forename: V T
authors.initials: VT
authors.lastname: Ang
authors.forename: R
authors.initials: R
authors.lastname: Jackson
authors.forename: J S
authors.initials: JS
authors.lastname: Jenkins
mesh_terms: D000324:Adrenocorticotropic Hormone / Q000097:blood / Q000378:metabolism*; D000328:Adult; D001127:Arginine Vasopressin / Q000097:blood / Q000378:metabolism*; D002404:Catheterization; D003346:Corticotropin-Releasing Hormone; D003480:Cushing Syndrome / Q000097:blood / Q000503:physiopathology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010121:Oxytocin / Q000097:blood / Q000378:metabolism*; D010902:Pituitary Gland / Q000098:blood supply / Q000378:metabolism*; D013268:Stimulation, Chemical
chemical_list: D001127:Arginine Vasopressin; D010121:Oxytocin; D000324:Adrenocorticotropic Hormone; D003346:Corticotropin-Releasing Hormone